MA50172A - Nucléosides substitués, nucléotides et analogues de ceux-ci - Google Patents

Nucléosides substitués, nucléotides et analogues de ceux-ci

Info

Publication number
MA50172A
MA50172A MA050172A MA50172A MA50172A MA 50172 A MA50172 A MA 50172A MA 050172 A MA050172 A MA 050172A MA 50172 A MA50172 A MA 50172A MA 50172 A MA50172 A MA 50172A
Authority
MA
Morocco
Prior art keywords
analogues
nucleotides
substituted nucleosides
nucleosides
substituted
Prior art date
Application number
MA050172A
Other languages
English (en)
Inventor
Leonid Beigelman
Jerome Deval
Marija Prhavc
Original Assignee
Janssen Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biopharma Inc filed Critical Janssen Biopharma Inc
Publication of MA50172A publication Critical patent/MA50172A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA050172A 2017-09-18 2018-09-18 Nucléosides substitués, nucléotides et analogues de ceux-ci MA50172A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762560110P 2017-09-18 2017-09-18

Publications (1)

Publication Number Publication Date
MA50172A true MA50172A (fr) 2021-04-07

Family

ID=63794555

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050172A MA50172A (fr) 2017-09-18 2018-09-18 Nucléosides substitués, nucléotides et analogues de ceux-ci

Country Status (17)

Country Link
US (2) US11149049B2 (fr)
EP (1) EP3684782A1 (fr)
JP (1) JP2020534361A (fr)
KR (1) KR102696517B1 (fr)
CN (1) CN111542531B (fr)
AU (1) AU2018332540B2 (fr)
CA (1) CA3075950A1 (fr)
CL (1) CL2020000685A1 (fr)
CR (1) CR20200126A (fr)
EA (1) EA202090775A1 (fr)
EC (1) ECSP20022130A (fr)
IL (1) IL273341A (fr)
MA (1) MA50172A (fr)
MX (1) MX2020002925A (fr)
PH (1) PH12020550114A1 (fr)
SG (1) SG11202002295QA (fr)
WO (1) WO2019053696A1 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424938B1 (fr) 2013-06-26 2020-07-22 Janssen BioPharma, Inc. Nucléosides, nucléotides et leurs analogues substitués par 4'-azidoalkyl
AU2015280234B2 (en) 2014-06-24 2021-04-01 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
ES2938859T3 (es) 2017-05-01 2023-04-17 Gilead Sciences Inc Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato
WO2019014247A1 (fr) 2017-07-11 2019-01-17 Gilead Sciences, Inc. Compositions comprenant un inhibiteur d'arn polymérase et de la cyclodextrine pour le traitement d'infections virales
US11149049B2 (en) 2017-09-18 2021-10-19 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2020202142A2 (fr) 2019-03-31 2020-10-08 Yeda Research And Development Co. Ltd. Composés anti-viraux et anti-tumoraux
CN110724174B (zh) * 2019-09-10 2021-02-05 广州六顺生物科技股份有限公司 吡咯并三嗪类化合物、组合物及其应用
CN110776512A (zh) * 2019-11-28 2020-02-11 成都傲飞生物化学品有限责任公司 一种核苷类似物的制备方法
CN118662520A (zh) 2020-01-27 2024-09-20 吉利德科学公司 用于治疗SARS CoV-2感染的方法
TWI874791B (zh) * 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
EP4106876B1 (fr) * 2020-02-18 2025-09-17 Gilead Sciences, Inc. Composés antiviraux
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
CN113292565B (zh) * 2020-02-24 2023-01-31 浙江森科建设有限公司 核苷类化合物及其制备方法和应用
CN113387954B (zh) * 2020-03-11 2024-03-19 上海特化医药科技有限公司 一种瑞德西韦中间体的制备方法
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
EP4132651B1 (fr) 2020-04-06 2026-03-18 Gilead Sciences, Inc. Formulations d'inhalation d'analogues de carbanucléosides à substitution 1'-cyano
CN112778310B (zh) * 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN111961057A (zh) * 2020-05-26 2020-11-20 李小冬 一种α构型核苷及其在治疗猫冠状病毒感染的应用
ES3041698T3 (en) 2020-05-29 2025-11-13 Gilead Sciences Inc Remdesivir for the treatment of viral infections
EP4172160A2 (fr) 2020-06-24 2023-05-03 Gilead Sciences, Inc. Analogues de 1'-cyano nucléoside et leurs utilisations
CN111793101B (zh) * 2020-07-17 2022-09-30 四川大学 C-核苷化合物的合成方法
CN116264827A (zh) 2020-07-24 2023-06-16 加利福尼亚大学董事会 抗病毒前药、药物制剂和方法
WO2022038539A2 (fr) 2020-08-18 2022-02-24 Yeda Research And Development Co. Ltd. Composés anti-viraux et anti-tumoraux
EP4200301B1 (fr) 2020-08-24 2025-02-26 Gilead Sciences, Inc. Composés phospholipidiques et leurs utilisations
HUE067491T2 (hu) * 2020-08-27 2024-10-28 Gilead Sciences Inc Vegyületek és eljárások vírusfertõzések kezelésére
AU2021342704A1 (en) * 2020-09-17 2023-05-04 Meletios Therapeutics Compounds for treating virus infections
CN112142810A (zh) * 2020-09-29 2020-12-29 佛山科学技术学院 核苷酸双氨基磷酸酯化合物、其药物组合物及其制备方法和应用
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
CN112300236A (zh) * 2020-10-21 2021-02-02 佛山科学技术学院 核苷酸混合氨基磷酸酯化合物、其药物组合物及其应用
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
CN114588159A (zh) * 2020-12-07 2022-06-07 成都傲科新技术有限责任公司 一种治疗猫冠状病毒感染的化合物及其应用
CN114634529A (zh) * 2020-12-15 2022-06-17 中国科学院大连化学物理研究所 一种氟代瑞德西韦及其合成方法
CN117964624A (zh) * 2020-12-30 2024-05-03 南方科技大学 一种具有治疗病毒感染功效的核苷类化合物及其用途
US12558364B2 (en) 2021-01-20 2026-02-24 Regents Of The University Of Minnesota Next generation remdesivir antivirals
WO2022166581A1 (fr) * 2021-02-07 2022-08-11 石家庄迪斯凯威医药科技有限公司 Dérivé nucléotidique, composite pharmaceutique de celui-ci et son utilisation
CN115215914B (zh) * 2021-04-15 2024-05-28 中国科学院上海药物研究所 核苷类似物及其用途
WO2022221870A1 (fr) * 2021-04-16 2022-10-20 Gilead Sciences, Inc. Procédés de préparation de carbanucléosides à l'aide d'amides
KR102923359B1 (ko) * 2021-04-16 2026-02-05 길리애드 사이언시즈, 인코포레이티드 아미드를 사용한 카르바뉴클레오시드를 제조하는 방법
EP4387977A1 (fr) 2021-08-18 2024-06-26 Gilead Sciences, Inc. Composés phospholipidiques et leurs procédés de production et d'utilisation
IL310854A (en) * 2021-08-20 2024-04-01 Shionogi & Co Nucleoside compounds and their drug derivatives possessing viral growth inhibitory activity
AU2023227794A1 (en) 2022-03-02 2024-10-17 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
CR20240367A (es) * 2022-03-03 2024-09-30 Gilead Sciences Inc Compuestos antivirales y métodos de elaboración y uso de los mismos.
CN114573590B (zh) * 2022-03-18 2023-11-14 苏州旺山旺水生物医药有限公司 一种四异丁酰基核苷类似物的制备方法及用途
WO2023186026A1 (fr) * 2022-03-31 2023-10-05 苏州旺山旺水生物医药有限公司 Procédé de préparation d'un analogue de nucléoside monoisobutyryle
EP4537827A4 (fr) * 2022-06-28 2025-11-05 Vigonvita Life Sciences Co Ltd Procédé de traitement d'une infection à coronavirus ou calicivirus félins
CN115894498A (zh) * 2022-10-01 2023-04-04 海化生命(厦门)科技有限公司 一种潜在抗病毒药物中间体bl及其合成方法
CN120152976A (zh) * 2022-10-23 2025-06-13 上海柯君医药科技有限公司 抗冠状病毒化合物及其组合物和用途
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
WO2025049699A1 (fr) * 2023-08-31 2025-03-06 Gilead Sciences, Inc. Composés antiviraux et leurs procédés de fabrication et d'utilisation
CN117509571B (zh) * 2023-11-01 2025-12-05 乐威医药（江苏）股份有限公司 一种连续化制备叠氮化碘的方法及其应用
CN118304315B (zh) * 2024-04-12 2025-03-25 深圳安泰维生物医药有限公司 一种核苷类化合物在制备抗呼吸道合胞病毒感染相关产品上的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
DZ3487A1 (fr) 2001-01-22 2002-07-25 Merck Sharp & Dohme Derives de nucleoside comme inhibiteurs de l'arn polymerase virale d'arn-dependant
WO2005020884A2 (fr) * 2003-05-14 2005-03-10 Idenix (Cayman) Limited Nucleosides pour traitement des infections a coronavirus, a togavirus et a picornavirus
AU2009240630B2 (en) 2008-04-23 2013-07-18 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment
AU2013216595B2 (en) * 2008-04-23 2016-07-28 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
EP2313102A2 (fr) * 2008-07-03 2011-04-27 Biota Scientific Management Nucléosides bicycliques et nucléotides convenant comme agents thérapeutiques
BR122021021135B1 (pt) * 2009-09-21 2022-08-30 Gilead Sciences, Inc Compostos análogos de 2-flúor substituído carba-nucleosídeo, composição farmacêutica e uso dos compostos análogos de 2´-flúoro substituído carbonucleosídeo
PH12013500035A1 (en) * 2010-07-22 2013-03-11 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
EA025341B1 (ru) * 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
AU2011305652B2 (en) * 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
EP2655392B1 (fr) * 2010-12-22 2018-04-18 Alios Biopharma, Inc. Analogues de nucléotides cycliques
US8980865B2 (en) * 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
AU2014331863C1 (en) * 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (fr) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. Inhibiteurs nucléosidiques substitués en 4' de la transcriptase inverse
AU2015280234B2 (en) * 2014-06-24 2021-04-01 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN117379452A (zh) 2014-06-24 2024-01-12 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸和其类似物
TWI740546B (zh) * 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
MA41213A (fr) * 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
SG10202109869XA (en) 2015-09-16 2021-10-28 Gilead Sciences Inc Methods for treating arenaviridae and coronaviridae virus infections
US11149049B2 (en) 2017-09-18 2021-10-19 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Also Published As

Publication number Publication date
MX2020002925A (es) 2020-10-05
KR102696517B1 (ko) 2024-08-21
CR20200126A (es) 2020-07-11
JP2020534361A (ja) 2020-11-26
EA202090775A1 (ru) 2020-07-06
AU2018332540B2 (en) 2023-10-05
BR112020005177A2 (pt) 2020-09-15
KR20200098483A (ko) 2020-08-20
CL2020000685A1 (es) 2020-10-23
EP3684782A1 (fr) 2020-07-29
IL273341A (en) 2020-05-31
US20210395288A1 (en) 2021-12-23
US20200277321A1 (en) 2020-09-03
CN111542531B (zh) 2024-07-19
CN111542531A (zh) 2020-08-14
WO2019053696A1 (fr) 2019-03-21
US11149049B2 (en) 2021-10-19
PH12020550114A1 (en) 2020-12-07
SG11202002295QA (en) 2020-04-29
AU2018332540A1 (en) 2020-04-30
CA3075950A1 (fr) 2019-03-21
US11773126B2 (en) 2023-10-03
ECSP20022130A (es) 2020-07-31

Similar Documents

Publication Publication Date Title
MA50172A (fr) Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41441A (fr) Nucléosides substitués, nucléotides et analogues de ceux-ci
MA45925A (fr) Nucléosides et nucléotides substitués et leurs analogues
IL249628A0 (en) Nucleosides, modified nucleotides and their analogs
IL249627A0 (en) Nucleosides, modified nucleotides and their analogs
LT3265102T (lt) Beta-d-2'-deoksi-2'alfa-fluor-2'-beta-c-pakeistieji-2-modifikuoti-n6- pakeistieji purino nukleotidai, skirti hcv gydymui
DK3207130T3 (da) Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme
EP3370731A4 (fr) Analogues nucléotidiques
DK3424938T3 (da) 4'-azidoalkylsubstituterede nukleosider, nukleotider og analoger deraf
DK3512863T3 (da) 2¿-substituerede-N6-substituerede purinnukleotider til behandling af RNA-virus
EP3350191A4 (fr) Analogues nucléotidiques
DK3347006T3 (da) Deutererede analoger af etifoxin, derivater deraf og anvendelser deraf
IL263852B (en) Oligonucleotides comprising modified nucleosides
EP3710462A4 (fr) Analogues de brartémicine
EP3556764A4 (fr) Dérivé de nucléoside et utilisation associée
EP3448392A4 (fr) Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées
IL261095A (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
EP3866932A4 (fr) Analogues de nucléosides de la 6-mercaptopurine
EP3418289A4 (fr) Nucléoside artificiel, nucléotide artificiel et oligonucléotide artificiel
IL273274A (en) Nucleoside modified phosphoramidites
DK3960182T3 (da) Sammensætninger indeholdende decitabin, 5-azacytidin og tetrahydrouridin samt anvendelser deraf
PT3248964T (pt) Moduladores tiazólicos de recetores a3 de adenosina
DK3433257T3 (da) Alkynylnukleosidanaloger som hæmmere af human rhinovirus
MA50025A (fr) Nucléosides de spirothiétane